Sameer ICH Guidelines
-
Upload
sameer22388 -
Category
Documents
-
view
230 -
download
0
Transcript of Sameer ICH Guidelines
-
7/31/2019 Sameer ICH Guidelines
1/17
Presented by :
Mr. Patel Sameer Ikbal
(M.Pharm,sem 1)
(Department of Pharmaceutics)
Supervised by
Dr.J.I.Dsouza
(Principal & HOD)
(Department of Pharmaceutics )
Guided by:
Miss Shalaka Patki
(Department of Pharmaceutics)
-
7/31/2019 Sameer ICH Guidelines
2/17
Objective- comprehensive set of safety guidelines touncover potential risks like carcinogenicity,genotoxicity and reprotoxicity.
A recent breakthrough- Non-clinical testing strategyfor assessing the QT interval prolongation liability
2/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
3/17
This document provides circumstances under which it isnecessary to undertake carcinogenicity studies on new
drugs. Provide risk factors as well as the intended indications and
duration of exposure.
3/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
4/17
Testing for Carcinogenicity of Pharmaceuticals
Guidance on the need to carry out carcinogenicity studiesin both mice and rats.
Testing procedures
4/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
5/17
Dose Selection for Carcinogenicity Studies ofPharmaceuticals
Criteria for the selection of the dose to be used incarcinogenicity studies
Provide implications on reducing the pain or discomfort ofthe animals at the maximally tolerated dose (MTD).
5/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
6/17
Guidance On Genotoxicity Testing And Data Interpretation ForPharmaceuticals Intended For Human Use
S2A: Guidance on Regulatory Genotoxicity Tests forPharmaceuticals :specific guidance and recommendations for in vitroand in vivo tests and on the evaluation of test results.
It includes a glossary of terms related to genotoxicity tests to improveconsistency in applications.
S2B: Genotoxicity: A Standard Battery for Genotoxicity Testingfor Pharmaceuticals; the identification of a standard set of assays to
be conducted for registration, and the extent of confirmatoryexperimentation in any particular genotoxicity assay in the standardbattery.
6/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
7/17
Note For Guidance On Toxicokinetics:The Assessment Of Systemic Exposure In ToxicityStudies
Provide guidance on developing test strategies intoxicokinetics and the need to integrate pharmacokinetics
with toxicity testing, in order to aid in the interpretation ofthe toxicology findings .
Promote rational study design development.
7/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
8/17
Pharmacokinetics: Dose Tissue Distribution Studies
This study is required when appropriate data cannot bederived from other sources
Data required-A comprehensive knowledge of theabsorption, distribution, metabolism and elimination of acompound is important for the interpretation of
pharmacology and toxicology studies.
useful for designing toxicology and pharmacology studies
8/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
9/17
Duration Of Chronic Toxicity Testing In Animals
safety evaluation of a medicinal product
for the development of medicinal products with theexception of those already covered by the ICH Guideline onSafety Studies for Biotechnological Products, e.g.,
Monoclonal antibodies, recombinant DNA proteins.
9/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
10/17
Detection Of Toxicity To Reproduction in MaleFertility
Guidance on tests for reproductive toxicity.
Defines the periods of treatment to be used in animals to
better reflect human exposure to medical products. Allow more specific identification of stages at risk
10/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
11/17
Addendum To Ich S6: Preclinical Safety Evaluation OfBiotechnology-derived Pharmaceuticals
Provide guidance on use of animal models of disease,determination of when genotoxicity assays andcarcinogenicity studies should be performed.
The impact of antibody formation on duration oftoxicology studies
Clarification on species selection, study design,immunogenicity, reproductive and developmental toxicityand assessment of carcinogenic potential.
11/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
12/17
Safety Pharmacology Studies for HumanPharmaceuticals
addresses the definition, objectives and scope of safetypharmacology studies
also addresses which studies are needed before initiation ofPhase 1 clinical studies as well as information needed formarketing.
1217TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
13/17
The Non-clinical Evaluation Of The Potential ForDelayed Ventricular Repolarization (Qt IntervalProlongation)
Guideline on non-clinical testing strategy for assessing thepotential of a test substance to delay ventricularrepolarization.
Includes non-clinical assays and integrated riskassessments
13/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
14/17
Immunotoxicity Studies for Human Pharmaceuticals Nonclinical testing for immunosuppressant induced by low
molecular weight drugs
It applies to new pharmaceuticals, as well as to marketed
drug products proposed for different indications changesin this change could result in unaddressed and relevanttoxicological issues
Also applicable during CT and following approval tomarket.
14/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
15/17
-
7/31/2019 Sameer ICH Guidelines
16/17
Photosafety Evaluation of Pharmaceuticals
This new Guideline on photosafety testing will be a
valuable adjunct to the guidanceprovided in the M3(R2)Guideline.
16/17TKCP WARANANAGAR
-
7/31/2019 Sameer ICH Guidelines
17/17
17/17TKCP WARANANAGAR